Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT Operating Cash Flow
Cash generated by the company's core business operations during the period.
Xtant Medical Holdings, Inc.AMEX: XTNT
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns negative
Q1 FY2026 operating cash flow was -$2.11M, compared with $1.28M a year earlier. Trailing-twelve-month operating cash flow was $9.15M.
Context
- Operating cash flow amounted to 9.4% of revenue in FY2025, down 0.8 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating cash flow holds near -$2.11M or moves back toward the trailing-twelve-month quarterly average of $2.29M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 12.55M USD
- Year-over-year change
- +205.5%
- 4-year CAGR
- +131.2%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.55M | +205.5% |
| FY2024 | 2024-12-31 | (11.9M) | -25.0% |
| FY2023 | 2023-12-31 | (9.52M) | -78.2% |
| FY2022 | 2022-12-31 | (5.34M) | -1316.6% |
| FY2021 | 2021-12-31 | 439K | — |
Operating Cash Flow vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 operating cash flow of $9.15M is the 5th largest of the 8 companies compared; the peer median is $25.35M.
- Its year-over-year change of +288.2% is the highest of 8, against a peer median of -19.3%.
- Operating cash flow amounts to 7.5% of revenue for XTNT, versus a peer median of 42.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $46.12M | +4.8% | +16.1% | 898.3% | |
| LTM Mar 2026 | $36.18M | -4.0% | -19.0% | 105.2% | |
| LTM Mar 2026 | $30.96M | -19.3% | +17.8% | 42.8% | |
| LTM Mar 2026 | $25.35M | +18.3% | +9.0% | — | |
| LTM Mar 2026 | $9.15M | +288.2% | — | 7.5% | |
| LTM Mar 2026 | $7.87M | -36.6% | -26.7% | 14.1% | |
| LTM Mar 2026 | $7.59M | -35.8% | -9.7% | 7.2% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $6.89M | -30.5% | +72.9% | — |
| Peer median (excluding XTNT) | $25.35M | -19.3% | +9.0% | 42.8% | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Depreciation & Amortization | 1.33M | 1.29M | 3.17M | 4.22M | 5.22M |
| Deferred Income Tax | 0 | 0 | (1.9M) | 21K | 0 |
| Stock-Based Compensation | 2.21M | 2.46M | 2.74M | 4.12M | 2.89M |
| Change in Working Capital | 793K | (2.81M) | (3.63M) | (5.35M) | (3.05M) |
| Accounts Receivables | (319K) | (3.94M) | (8.74M) | (755K) | (591K) |
| Inventory | 2.62M | (1.15M) | (1.89M) | (2.49M) | (2M) |
| Accounts Payables | (332K) | 875K | 2.98M | 1.03M | (3.12M) |
| Other Working Capital | (1.18M) | 1.41M | 4.01M | (3.13M) | 2.66M |
| Other Non-Cash Items | 954K | 2.2M | (10.55M) | 1.54M | 2.5M |
| Operating Cash Flow | 439K | (5.34M) | (9.52M) | (11.9M) | 12.55M |
| Capital Expenditures | (2.12M) | (1.76M) | (1.46M) | (4.11M) | (2.38M) |
| Acquisitions (Net) | 0 | 0 | (23.5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 225K | 205K | 175K | 383K | 10.28M |
| Investing Cash Flow | (1.89M) | (1.56M) | (24.78M) | (3.73M) | 7.9M |
| Debt Repayment | (592K) | (291K) | 6.18M | 12.43M | (9.33M) |
| Common Stock Issued | 18.43M | 9.31M | 14.01M | 4.46M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (65K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (337K) | 9.07M | (500K) | (816K) | (175K) |
| Financing Cash Flow | 17.5M | 9.02M | 19.69M | 16.07M | (9.57M) |
| Effect of Forex Changes | 0 | 0 | 24K | (149K) | 232K |
| Net Change in Cash | 16.05M | 2.12M | (14.58M) | 298K | 11.11M |
| Free Cash Flow | (1.68M) | (7.11M) | (10.97M) | (16.01M) | 10.16M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.